Chuo University ELSI Center and The University of Osaka established the Research Center on Ethical, Legal and Social Issues (The University of Osaka ELSI Center) jointly hosted the "University ELSI Summit", a two-day event held on March 15^th and 16^th, 2025 (Saturday-Sunday) at Chuo University's Korakuen Campus (Bunkyo-ku, Tokyo, Japan).

    ELSI (Ethical, Legal and Social Issues) and RRI (Responsible Research and Innovation) are seeing rapid development globally. These approaches are being examined across various fields both domestically and internationally. The ELSI University Summit focused on ELSI and RRI initiatives in academia and industry. These initiatives concentrate on research areas related to advanced AI and social challenges. The summit included reports from multiple stakeholders responsible for development, utilization, and regulation — including the business community, government agencies, educational institutions, science and engineering researchers, and humanities researchers. In addition, through Q&A sessions and panel discussions, the summit engaged in intensive discussions about their respective roles and the importance of collaboration. The event attracted a total of 607 on-site participants and online ones.

Signaling a major advance in small-data AI for medical imaging, a research team from Institute of Science Tokyo has developed a novel artificial intelligence model called “MHP-Net,” which delivers cutting-edge performance in liver tumor segmentation with a limited dataset. Unlike conventional models that require thousands of patient cases, this model uses sampling of 3D patches obtained from 7 to 28 tumors. Also, it outperforms the top entry of the MICCAI 2017 (worldwide liver tumor segmentation competition).

New research led by the University of Seville (Spain) reveals that brown bear distribution across Europe and Turkey is strongly influenced by the availability of species in their diet, highlighting the critical role of species interactions in shaping ecosystems amid climate change and land use shifts.

ITM Isotope Technologies Munich SE (ITM) and Institut Laue-Langevin (ILL) today announced an extension of their collaboration for medical radioisotope production , originally established in 2009. Under the terms of the renewed agreement, ITM will receive priority access to half of the available neutron irradiation capacity at the ILL’s High-Flux Reactor, its neutron irradiation facility, for the production of non-carrier-added Lutetium-177 (n.c.a. ¹⁷⁷Lu), a critical medical radioisotope used for radiopharmaceutical therapies for cancer treatment and diagnosis.

A patch containing tens of millions of microscopic nanoneedles could soon replace traditional biopsies, scientists have found. The patch offers a painless and less invasive alternative for millions of patients worldwide who undergo biopsies each year to detect and monitor diseases like cancer and Alzheimer’s.